Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Bernhard

Showing results (211-220 of 250) with videos related to

Pageof 25
Sort By:
Progres En Urologie : Journal De L'Association Francaise D'Urologie Et De La Societe Francaise D'Urologie|November 7, 2015
[Not Available]G Robert, N Barry Delongchamps, A Descazeaud, et al.
International Journal of Cancer|June 16, 2012
G-CSF rescues tumor growth and neo-angiogenesis during liver metastasis under host angiopoietin-2 deficiencyJae Hong Im, Thomas Tapmeier, Lukxmi Balathasan, et al.
Radiation Research|August 10, 2000
Farnesyltransferase inhibitors potentiate the antitumor effect of radiation on a human tumor xenograft expressing activated HRASE Cohen-Jonathan, R J Muschel, W Gillies McKenna, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 16, 2002
Local recurrence in head and neck cancer: relationship to radiation resistance and signal transductionAnjali K Gupta, W Gillies McKenna, Charles N Weber, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 15, 2002
A Phase I trial of the farnesyltransferase inhibitor L-778,123 and radiotherapy for locally advanced lung and head and neck cancerStephen M Hahn, Eric J Bernhard, William Regine, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 30, 2015
Preoperative versus postoperative docetaxel-cisplatin-fluorouracil (TCF) chemotherapy in locally advanced resectable gastric carcinoma: 10-year follow-up of the SAKK 43/99 phase III trialN Fazio, R Biffi, R Maibach, et al.
British Journal of Cancer|November 29, 2007
Quality of life and quality-adjusted survival (Q-TWiST) in patients receiving dose-intensive or standard dose chemotherapy for high-risk primary breast cancerJ Bernhard, D Zahrieh, J J Zhang, et al.
Progres En Urologie : Journal De L'Association Francaise D'Urologie Et De La Societe Francaise D'Urologie|October 14, 2015
[Not Available]G Pignot, R Bahi, K Bensalah, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 22, 2016
Do all patients with advanced HER2 positive breast cancer need upfront-chemo when receiving trastuzumab? Randomized phase III trial SAKK 22/99O Pagani, D Klingbiel, T Ruhstaller, et al.
British Journal of Cancer|November 17, 2004
Quantifying trade-offs: quality of life and quality-adjusted survival in a randomised trial of chemotherapy in postmenopausal patients with lymph node-negative breast cancerJ Bernhard, D Zahrieh, A S Coates, et al.
Pageof 25

Showing results (211-220 of 250) with videos related to

Sort By:
Pageof 25
Progres En Urologie : Journal De L'Association Francaise D'Urologie Et De La Societe Francaise D'Urologie|November 7, 2015
[Not Available]G Robert, N Barry Delongchamps, A Descazeaud, et al.
International Journal of Cancer|June 16, 2012
G-CSF rescues tumor growth and neo-angiogenesis during liver metastasis under host angiopoietin-2 deficiencyJae Hong Im, Thomas Tapmeier, Lukxmi Balathasan, et al.
Radiation Research|August 10, 2000
Farnesyltransferase inhibitors potentiate the antitumor effect of radiation on a human tumor xenograft expressing activated HRASE Cohen-Jonathan, R J Muschel, W Gillies McKenna, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 16, 2002
Local recurrence in head and neck cancer: relationship to radiation resistance and signal transductionAnjali K Gupta, W Gillies McKenna, Charles N Weber, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 15, 2002
A Phase I trial of the farnesyltransferase inhibitor L-778,123 and radiotherapy for locally advanced lung and head and neck cancerStephen M Hahn, Eric J Bernhard, William Regine, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 30, 2015
Preoperative versus postoperative docetaxel-cisplatin-fluorouracil (TCF) chemotherapy in locally advanced resectable gastric carcinoma: 10-year follow-up of the SAKK 43/99 phase III trialN Fazio, R Biffi, R Maibach, et al.
British Journal of Cancer|November 29, 2007
Quality of life and quality-adjusted survival (Q-TWiST) in patients receiving dose-intensive or standard dose chemotherapy for high-risk primary breast cancerJ Bernhard, D Zahrieh, J J Zhang, et al.
Progres En Urologie : Journal De L'Association Francaise D'Urologie Et De La Societe Francaise D'Urologie|October 14, 2015
[Not Available]G Pignot, R Bahi, K Bensalah, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 22, 2016
Do all patients with advanced HER2 positive breast cancer need upfront-chemo when receiving trastuzumab? Randomized phase III trial SAKK 22/99O Pagani, D Klingbiel, T Ruhstaller, et al.
British Journal of Cancer|November 17, 2004
Quantifying trade-offs: quality of life and quality-adjusted survival in a randomised trial of chemotherapy in postmenopausal patients with lymph node-negative breast cancerJ Bernhard, D Zahrieh, A S Coates, et al.
Pageof 25